LY 3972406
Alternative Names: DES-7114; LY-3972406Latest Information Update: 08 Feb 2024
At a glance
- Originator D E Shaw Research
- Developer Eli Lilly and Company
- Class Anti-inflammatories; Antipsoriatics; Skin disorder therapies; Small molecules
- Mechanism of Action Kv1.3 potassium channel inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Plaque psoriasis
Most Recent Events
- 06 Dec 2023 Phase-II clinical trials in Plaque psoriasis in USA (PO) (NCT06176768)
- 13 Jun 2022 Phase-I clinical trials in Immunological disorders (In volunteers) in USA prior to June 2022
- 13 Jun 2022 D. E. Shaw Research completes the phase I trials in Immunological disorders (In volunteers) in USA prior to June 2022 (D. E. Shaw Research website, June 2022)